Study: Chlorhexidine Baths Did Not Increase Resistant MRSA
The retrospective cohort study of patients admitted to the Barnes-Jewish Hospital ICU in St. Louis, Missouri from 2005 through 2012 included more than 500 randomly selected isolates of MRSA from surveillance cultures to determine drug resistance. The prevalence of CHG-resistant MRSA isolates fell from 6.2 percent in the year chlorhexidine bathing began to zero to 1.5 percent from 2006 to 2009. The prevalence spiked to 16.9 percent in 2009 and 2010 before subsiding to 4.6 and 7.7 percent in 2011 and 2012. The researchers attribute increased prevalence at certain points to patients admitted to the ICU already colonised with MRSA prior to chlorhexidine exposure.
David Warren, MD, MPH, lead author of the study and Associate Professor of Medicine in the Division of Infectious Diseases at Washington University School of Medicine and Hospital Epidemiologist at Barnes-Jewish Hospital in St. Louis, observed: "There has been concern in the healthcare community about the impact of routine, daily chlorhexidine (CHG) bathing on fostering the spread of bacteria resistant to this agent. We did not see sustained increase in MRSA resistant to CHG.”
See Also: Findings Do Not Support Chlorhexidine Bathing in ICUs
However, other studies have conflicting findings, and Derek Angus wrote in JAMA in 2015 that “the largest benefit appears to be in settings where the baseline prevalence of multidrug-resistant organisms is high. In these settings, the same benefits potentially could be gained through other approaches, such as improved hand hygiene, which may be safer and less likely to affect the ecology of bacterial resistance in the ICU.”
Image credit: Wikimedia Commons
Published on : Mon, 8 Feb 2016
Print as PDF
The technical and clinical reference standard for all B·R·A·H·M·S PCT assays. All clinical cut-offs and algorithms were developed based on B·R·A·H·M·S PCT sensitive KRYPTOR. Homogeneous immunoassay for the quantitative d
Medos customized tubing sets have been individually designed, so that all customer requirements, depending on application and need can be realized. Furthermore tubing sets can be refined by rheoparin or x.eed coating.
NovaPort cannulas are designed specially to meet the needs of extracorporeal lung and heart support circuits and perioperative perfusion in minimally invasive heart surgery.All blood-contact surfaces of the NovaPort cannulas are coated with the bio- and...
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...
The fully featured ICU ventilator, HAMILTON-MR1, guarantees uncompromised continuous ventilation care from the ICU to the MRI scanner and back. Its reliability and high performance, with advanced lung-protective strategies and patient-adaptive modes,...